Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 39 Show results per page	View Search Criteria \| Help With Results

Last Modified: 7/11/2007 First Published: 3/22/2007


1.		Phase II/III Randomized Study of Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Biomarker/Laboratory analysis, Treatment				Active				Any age				Other				UHW-AML16 EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480


2.		A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				60 and over				Pharmaceutical / Industry				CLO34100405 NCT00317642


3.		Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and under				NCI, Other				TOTXVI NCT00549848


4.		Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				60 and over				Other				F040114019 UAB 0341, NCT00081822

Last Modified: 5/27/2008 First Published: 3/17/2006


5.		Phase I/II Study of Clofarabine in Patients With Relapsed or Refractory T-Cell or B-Cell Aggressive Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				OSSC-0408 WIRB-20050514, NCT00305721


6.		A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				1 to 21				Pharmaceutical / Industry				CLO21800205 NCT00315705

Last Modified: 12/28/2006 First Published: 12/21/2006


7.		Phase I/II Study of Clofarabine in Patients With Relapsed or Refractory T-Cell or Natural Killer-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				2 and over				NCI				MSKCC-06065 NCT00416351

Last Modified: 7/11/2007 First Published: 1/5/2007


8.		Phase I/II Study of Cytoreduction Therapy Comprising Clofarabine, Melphalan, and Thiotepa Followed By Allogeneic Unmodified Hematopoietic Stem Cell Transplantion in Patients With High-Risk and/or Advanced Hematologic Malignancies or Other Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Under 55				NCI				MSKCC-06125 NCT00423514


9.		Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				21 and over				Other				2005-0552 NCT00412243


10.		Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				1066306 (0408) NCT00156013

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute